Litcius/Paper detail

Crosstalk between miRNAs and signaling pathways in the development of drug resistance in breast cancer

Reza Amiri, Poorya Najjari Nabi, Ahmad Fazilat, Fatemeh Roshani, Alireza Nouhi Kararoudi, Mohsen Hemmati-Dinarvand, Mohammad Valilo

2024Hormone Molecular Biology and Clinical Investigation12 citationsDOIOpen Access PDF

Abstract

One of the biggest challenges of today's society is cancer, which imposes a significant financial, emotional and spiritual burden on human life. Breast cancer (BC) is one of the most common cancers that affects people in society, especially women, and due to advanced treatment strategies and primary prevention, it is still the second cause of cancer-related deaths in society. Various genetic and environmental factors are involved in the development of BC. MicroRNAs (miRNA)s are non-coding RNAs, that the degradation or inhibition of them plays an important role in the prevention or development of cancer by modulating many cellular pathways including apoptosis, drug resistance, and tumorigenesis. Drug resistance is one of the important defense mechanisms of cancer cells against anticancer drugs and is considered one of the main causes of cancer treatment failure. Different miRNAs, including mir-7, mir-21, mir-31, and mir-124 control different cell activities, including drug resistance, through different pathways, including PI3K/AKT/mTOR, TGF-β, STAT3, and NF-kB. Therefore, cell signaling pathways are one of the important factors that miRNAs control cellular activities. Hence, in this study, we decided to highlight an overview of the relationship between miRNAs and signaling pathways in the development of drug resistance in BC.

Topics & Concepts

microRNACrosstalkCarcinogenesisPI3K/AKT/mTOR pathwayDrug resistanceBreast cancerCancerSignal transductionCancer researchProtein kinase BBiologyBioinformaticsMedicineGeneticsGenePhysicsOpticsMicroRNA in disease regulationCircular RNAs in diseasesCancer Mechanisms and Therapy
Crosstalk between miRNAs and signaling pathways in the development of drug resistance in breast cancer | Litcius